disposition of the cognition activator tacrine in rats, dogs, and humans. Species comparisons. Drug Metab Dispos 1997; 25(5):590–7.
178 178 Madden S, Spaldin V, Hayes RN, Woolf TF, Pool WF, Park BK. Species variation in the bioactivation of tacrine by hepatic microsomes. Xenobiotica 1995; 25(1):103–16.
179 179 Sung JH, Yu KH, Park JS, Tsuruo T, Kim DD, Shim CK, et al. Saturable distribution of tacrine into the striatal extracellular fluid of the rat: evidence of involvement of multiple organic cation transporters in the transport. Drug Metab Dispos 2005; 33(3):440–8.
180 180 Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology 1996; 23(6):1429–35.
181 181 Simon T, Becquemont L, Mary‐Krause M, de Waziers I, Beaune P, Funck‐Brentano C, et al. Combined glutathione‐S‐transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther 2000; 67(4):432–7.
182 182 Becquemont L, Lecoeur S, Simon T, Beaune P, Funck‐Brentano C, Jaillon P. Glutathione S‐transferase theta genetic polymorphism might influence tacrine hepatotoxicity in Alzheimer's patients. Pharmacogenetics 1997; 7(3):251–3.
183 183 Biglin KE, Faraon MS, Constance TD, Lieh‐Lai M. Drug‐induced torsades de pointes: a possible interaction of terfenadine and erythromycin. Ann Pharmacother 1994; 28(2):282.
184 184 Wynn RL. Erythromycin and ketoconazole (Nizoral) associated with terfenadine (Seldane)‐induced ventricular arrhythmias. Gen Dent 1993; 41(1):27–9.
185 185 Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR, Jr. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52(3):231–8.
186 186 Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269 (12):1532–6.
187 187 Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine‐ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269 (12):1513–8.
188 188 Zimmermann M, Duruz H, Guinand O, Broccard O, Levy P, Lacatis D, et al. Torsades de Pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992; 13(7):1002–3.
189 189 Kamisako T, Adachi Y, Nakagawa H, Yamamoto T. Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma. Intern Med 1995; 34(2):92–5.
190 190 Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy 1999; 29 Suppl 3:163–70; discussion 71‐3.
191 191 Balian JD, Rahman A. Metabolic drug‐drug interactions: perspective from FDA medical and clinical pharmacology reviewers. Adv Pharmacol 1997; 43:231–8.
192 192 Davit B, Reynolds K, Yuan R, Ajayi F, Conner D, Fadiran E, et al. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug‐drug interactions: impact on labeling. J Clin Pharmacol 1999; 39(9):899–910.
193 193 Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008; 48(6):662–70.
194 194 Yu J, Petrie ID, Levy RH, Ragueneau‐Majlessi I. Mechanisms and clinical significance of pharmacokinetic‐based drug‐drug interactions with drugs approved by the U.S. Food and Drug Administration in 2017. Drug Metab Dispos 2019; 47(2):135–44.
195 195 Aslanian R, Piwinski JJ, Zhu X, Priestley T, Sorota S, Du XY, et al. Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett 2009; 19 (17):5043–7.
196 196 Kamiya K, Niwa R, Morishima M, Honjo H, Sanguinetti MC. Molecular determinants of hERG channel block by terfenadine and cisapride. J Pharmacol Sci 2008; 108(3):301–7.
197 197 Roy M, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996; 94(4):817–23.
198 198 Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996; 385 (1–2):77–80.
199 199 Raeissi SD, Hidalgo IJ, Segura‐Aguilar J, Artursson P. Interplay between CYP3A‐mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco‐2 (TC7) cell monolayers. Pharm Res 1999; 16(5):625–32.
200 200 Jurima‐Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994; 22(6):849–57.
201 201 Herings RM, Stricker BH, Leufkens HG, Bakker A, Sturmans F, Urquhart J. Public health problems and the rapid estimation of the size of the population at risk. Torsades de pointes and the use of terfenadine and astemizole in The Netherlands. Pharm World Sci 1993; 15(5):212–8.
202 202 Pohjola‐Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993; 45(2):191–3.
203 203 Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP. Torsades de pointes induced by erythromycin and terfenadine. Am J Emerg Med 1994; 12(6):636–8.
204 204 Pohjola‐Sintonen S. Treatment with terfenadine and ketoconazole or itraconazole can cause torsades de pointes ventricular tachycardia. Duodecim 1993; 109(2):164–6.
205 205 Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59(4):383–8.
206 206 Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, et al. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 1997; 52(4):311–5.
207 207 Honig PK, Wortham DC, Lazarev A, Cantilena LR. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 1996; 36(4):345–51.
208 208 Rau SE, Bend JR, Arnold MO, Tran LT, Spence JD, Bailey DG. Grapefruit juice‐terfenadine single‐dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther 1997; 61(4):401–9.
209 209 Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000; 95(1):272–6.
210 210 Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129(1):36–8.
211 211 Herrine SK, Choudhary C. Severe hepatotoxicity associated with troglitazone. Ann Intern Med 1999; 130(2):163–4.
212 212 Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4(6):489–99.
213 213 Meier Y, Cavallaro M, Roos M, Pauli‐Magnus C, Folkers G, Meier PJ, et al. Incidence of drug‐induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61(2):135–43.
214 214 Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug‐induced liver injury in the general population of Iceland. Gastroenterology. 2013; 144(7):1419–25, 25 e1‐3; quiz e19‐20.
215 215 Faich GA, Moseley RH. Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf 2001; 10(6):537–47.
216 216 Dixit VA, Bharatam PV. Toxic metabolite formation from Troglitazone (TGZ): new insights from a DFT study. Chem Res Toxicol 2011; 24(7):1113–22.
217 217 Prabhu S, Fackett A, Lloyd S, McClellan HA, Terrell CM, Silber PM, et al. Identification of glutathione conjugates